News 23andMe doses first patient in ph2a anti-tumour monotherapy Additionally, the company will be making investor presentations today and next week.
Oncology Optimised cancer drug dosing - FDA guidelines’ quantum leap Dose optimisation guidance for clinical trials was released by the FDA this January.
Oncology JP Morgan 2023 - Raj Chopra On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics.
Oncology After a slow start for expensive CAR-T therapies, drug devel... There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
